Welcome to visit Zhongnan Medical Journal Press Series journal website!
Zhongnan Medical Journal Press Series of Journals Center for Evidence-Based and Translational Medicine of Wuhan University

The title
  • The title
  • The keywords
  • The author
Submit中文版

HomeArticlesVol 34,2024 No.4Detail

Transurethral plasmakinetic resection of prostate in high-risk benign prostatic hyperplasia patients: a multicenter prospective study

Published on Apr. 29, 2024Total Views: 717 timesTotal Downloads: 922 timesDownloadMobile

Author: LI Fei 1, 2 GENG Jie 3 CHEN Hongbo 4 ZHOU Zhijun 5 LIU Xiaohua 6 SHI Hongbo 7 DU Dan 8 ZHU Tao 9 ZHANG Jingyu 10 LI Xiaodong 11 QUE Hui 12 SONG Hongfei 13 YAO Qisheng 14 DOU  Zhongling 15 RUAN Jianzhong 16 ZHENG Jiang 17 ZHU Ziqing 18 REN Xuanyi 19 HUANG Qiao 2 GONG Kan 20 LIU Tongzu 1 HE Dalin 21 ZENG Xiantao 1, 2

Affiliation: 1. Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China 2. Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China 3. Department of Urology, Suizhou Central Hospital, Suizhou 441300, Hubei Province, China 4. Department of Urology, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi Tujia and Miao Autonomous Prefecture 445000, Hubei Province, China 5. Department of Urology, The First People’s Hospital of Tianmen in Hubei Province, Tianmen 431700, Hubei Province, China 6. Department of Urology, Minda Hospital of Hubei Minzu University, Enshi Tujia and Miao Autonomous Prefecture 445000, Hubei Province, China 7. Department of Urology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Sciences, Xiangyang 441100, Hubei Province, China 8. Department of Urology, The Second People's Hospital of Yichang, Yichang 443000, Hubei Province, China 9. Department of Urology, The Sixth Hospital of Wuhan, Wuhan 430015, China 10. Department of Urology, The Third Hospital of Wuhan, Wuhan 430060, China 11. Department of Urology, Huaihe Hospital of Henan University, Kaifeng 475000, Henan Province, China 12. Department of Urology, Huanggang Central Hospital, Huanggang 438000, Hubei Province, China 13. Department of Urology, Qianjiang Central Hospital, Qianjiang 433100, Hubei Province, China 14. Department of Urology, Taihe Hospital, Affiliated Hospital of Hubei University of Medicine, Shiyan 442000, Hubei Province, China 15. Department of Urology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang 471000, Henan Province, China 16. Department of Urology, Xiaogan First People's Hospital, Xiaogan 432000, Hubei Province, China 17. Department of Urology, The First People's Hospital of Jingzhou, Jingzhou 434000, Hubei Province, China 18. Department of Urology, CR&WISCO General Hospital, Wuhan 430080, China 19. Department of Urology, Kaifeng Central Hospital, Kaifeng 475000, Henan Province, China 20. Department of Urology, Peking University First Hospital, Beijing 100034, China 21. Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China

Keywords: Transurethral plasmakinetic resection of prostate Benign prostatic hyperplasia High-risk patients Cardiovascular diseases

DOI: 10.12173/j.issn.1004-5511.202402013

Reference: Li F, Geng J, Chen HB, Zhou ZJ, Liu XH, Shi HB, Du D, Zhu T, Zhang JY, Li XD, Que H, Song HF, Yao QS, Dou ZL, Ruan JY, Zheng J, Zhu ZJ, Ren XY, Huang Q, Gong K, Liu TZ, He, DL, Zeng XT. Transurethral plasmakinetic resection of prostate in high-risk benign prostatic hyperplasia patients: a multicenter prospective study[J]. Yixue Xinzhi Zazhi, 2024, 34(4): 381-390. DOI: 10.12173/j.issn.1004-5511.202402013.[Article in Chinese]

  • Abstract
  • Full-text
  • References
Abstract

Objective  To investigate the clinical efficacy of transurethral plasmakinetic resection of prostate (TUPKP) in treating high-risk benign prostatic hyperplasia (BPH) patients.

Methods  A prospective multicenter study design was employed. Patients with high-risk BPH treated with TUPKP were enrolled in the urology departments of 20 hospitals nationwide according to the inclusion and exclusion criteria. Relevant data regarding patient baseline, perioperative period, and 3-month postoperative follow-up were analyzed to evaluate efficacy and safety.

Results   From September 2016 to December 2018, a total of 229 high-risk BPH patients were enrolled. Compared to baseline at the 3-month follow-up, the change in the International Prostate Symptom Score was -17.28[95%CI(-18.02, -16.54)], the change in maximum urinary flow rate was 5.61[95%CI(0.68, 10.54)]mL·s-1, the change in residual urine volume was -84.50 [95%CI(-96.49, -72.51)] mL, and the change in quality of life score was -3.24[95%CI(-3.42, -3.06)],all showing significant differences(P<0.05). The incidence of intraoperative and postoperative complications was low, and no surgery-related adverse events occurred.

Conclusion  TUPKP can be used to treat high-risk BPH patients, and it is recommended to be performed by skilled surgeons.

Full-text
Please download the PDF version to read the full text: download
References

1. Chughtai B, Forde JC, Thomas DD, et al. Benign prostatic hyperplasia[J]. Nat Rev Dis Primers, 2016, 2: 16031. DOI: 10.1038/nrdp.2016.31.

2. GBD 2019 Benign Prostatic Hyperplasia Collaborators. The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet Healthy Longev, 2022, 3(11): e754-e776. DOI: 10.1016/s2666-7568(22)00213-6.

3. Gravas S, Gacci M, Gratzke C, et al. Summary paper on the 2023 European association of urology guidelines on the management of non-neurogenic male lower urinary tract symptoms[J]. Eur Urol, 2023, 84(2): 207-222. DOI: 10.1016/j.eururo.2023.04.008.

4. Zhu C, Wang DQ, Zi H, et al. Epidemiological trends of urinary tract infections, urolithiasis and benign prostatic hyperplasia in 203 countries and territories from 1990 to 2019[J]. Mil Med Res, 2021, 8(1): 64. DOI: 10.1186/s40779-021-00359-8.

5. 顾佳敏, 朱聪, 訾豪, 等. 1990-2019年中国良性前列腺增生疾病负担分析[J]. 解放军医学杂志, 2021, 46(10): 984-988. [Gu JM, Zhu C, Zi H, et al. Analysis of the disease burden of benign prostatic hyperplasia in China from 1990 to 2019[J]. Medical Journal of Chinese People's Liberation Army, 2021, 46(10): 984-988.] DOI: 10.11855/j.issn.0577-7402.2021.10.05.

6. 罗丽莎, 栾航航, 朱聪, 等. 1990-2019年中国、日本与韩国的良性前列腺增生疾病负担比较[J]. 现代泌尿外科杂志, 2023, 28(6): 506-512. [Luo LS, Luan HH, Zhu C, et al. Disease burden of benign prostatic hyperplasia in China, Japan and South Korea from1990 to 2019: a comparative study[J]. Journal of Modern Urology, 2023, 28(6): 506-512.] DOI: 10.3969/j.issn.1009-8291.2023.06.010.

7. Yang Z, Wang X, Liu T. Thulium laser enucleation versus plasmakinetic resection of the prostate: a randomized prospective trial with 18-month follow-up[J]. Urology, 2013, 81(2): 396-400. DOI: 10.1016/j.urology.2012.08.069.

8. Huang X, Wang L, Wang XH, et al. Bipolar transurethral resection of the prostate causes deeper coagulation depth and less bleeding than monopolar transurethral prostatectomy[J]. Urology, 2012, 80(5): 1116-1120. DOI: 10.1016/j.urology.2012.07.024.

9. 朱泳新, 杨增士, 叶宁, 等. 经尿道前列腺等离子电切术治疗老年高危大体积前列腺增生疗效及对机体氧化应激的影响[J]. 吉林医学, 2022, 43(8): 2223-2225. [Zhu YX, Yang ZS, Ye N, et al. Efficacy of transurethral plasma resection of the prostate in the treatment of high-risk and largevolume benign prostatic hyperplasia and its effect on the body's oxidative stress[J]. Jilin Medical Journal, 2022, 43(8): 2223-2225.] DOI: 10.3969/j.issn.1004-0412.2022.08.071.

10 .黄玉清, 张良, 魏胜红. 经尿道等离子前列腺剜除术与电切术治疗高危良性前列腺增生症的临床效果[J]. 中国当代医药, 2023, 30(31): 72-76. [Huang YQ, Zhang  L, Wei SH. Clinical effect of transurethral enucleation of the prostate and transurethral resection of the prostate in treating the high-risk benign prostatic hyperplasia[J]. China Modern Medicine, 2023, 30(31): 72-76.] DOI: 10. 3969/j.issn.1674-4721.2023.31.018.

11. 胡伟强, 高海权. 经尿道等离子前列腺剜除术与电切术治疗高危良性前列腺增生症的临床观察[J]. 贵州医药, 2023, 47(8): 1250-1252. [Hu WQ, Gao HQ. Clinical observation of transurethral plasmakineti enucleation of the prostate and transurethral resection of the prostate in the treatment of high-risk benign prostatic hyperplasia[J]. Guizhou Medical Journal, 2023, 47(8): 1250-1252.] DOI: 10.3969/j.issn.1000-744X.2023.08.045.

12. Huang SW, Tsai CY, Tseng CS, et al. Comparative efficacy and safety of new surgical treatments for benign prostatic hyperplasia: systematic review and network Meta-analysis[J]. BMJ, 2019, 367: l5919. DOI: 10.1136/bmj.l5919.

13. 李绪辉, 訾豪, 黄兴, 等. 经尿道前列腺等离子双极电切术与剜除术治疗良性前列腺增生的有效性和安全性的系统评价和Meta分析[J]. 医学新知, 2021, 31(2): 100-114. [Li XH, Zi H, Huang X, et al. Efficacy and safety of transurethral plasmakinetic resection of prostate versus transurethral plasmakinetic enucleation of prostate in treating benign prostate hyperplasia: a systematic review and Meta-analysis[J]. Yixue Xinzhi Zazhi, 2021, 31(2): 100-114.] DOI: 10.12173/j.issn.1004-5511.2021.02.03.

14. 刘俊峰, 刘春晓, 谭朝晖, 等. 经尿道双极等离子前列腺剜除术与电切术后尿失禁发生率的随机对照研究[J]. 中华男科学杂志, 2014, 20(2): 165-168. [Liu JF, Liu CX, Tan ZH, et al. Transurethral bipolar plasmakinetic enucleation and resection versus transurethral bipolar plasmakinetic resection of the prostate for BPH: a randomized controlled trial on the incidence of postoperative urinary incontinence[J]. National Journal of Andrology, 2014, 20(2): 165-168.] DOI: 10.13263/j.cnki.nja.2014.02.014.

15. Mayer EK, Kroeze SGC, Chopra S, et al. Examining the 'gold standard': a comparative critical analysis of three consecutive decades of monopolar transurethral resection of the prostate (TURP) outcomes[J]. BJU Int, 2012, 110(11): 1595-1601. DOI: 10.1111/j.1464-410X.2012.11119.x.

16. Zhang J, Wang Y, Li S, et al. Efficacy and safety evaluation of transurethral resection of the prostate versus plasmakinetic enucleation of the prostate in the treatment of massive benign prostatic hyperplasia[J]. Urol Int, 2021, 105(9-10): 735-742. DOI: 10.1159/000511116.

17. Raj MD, McDonald C, Brooks AJ, et al. Stopping anticoagulation before turp does not appear to increase perioperative cardiovascular complications[J]. Urology, 2011, 78(6): 1380-1384. DOI: 10.1016/j.urology.2011.05.053.

18. Reich O, Gratzke C, Bachmann A, et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients[J]. J Urol, 2008, 180(1): 246-249. DOI: 10.1016/j.juro.2008.03.058.

19. 汪洋, 李志鹏, 王可兵. 经尿道前列腺钬激光剜除术并发症的研究进展[J]. 中华腔镜泌尿外科杂志(电子版), 2022, 16(1): 93-96. [Wang Y, Li ZP, Wang KB. Research progress on complications of transurethral holmium laser enucleation of prostate[J]. Chinese Journal of Endourology(Electronic Edition), 2022, 16(1): 93-96.]DOI: 10.3877/cma.j.issn.1674-3253.2022.01.022.

20. Ahyai SA, Gilling P, Kaplan SA, et al. Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement[J]. Eur Urol, 2010, 58(3): 384-397. DOI: 10.1016/j.eururo.2010.06.005.

21. Michielsen DPJ, Debacker T, De Boe V, et al. Bipolar transurethral resection in saline-an alternative surgical treatment for bladder outlet obstruction?[J]. J Urol, 2007, 178(5): 2035-2039. DOI: 10.1016/j.juro.2007.07.038.

22. Tang Y, Li J, Pu C, et al. Bipolar transurethral resection versus monopolar transurethral resection for benign prostatic hypertrophy: a systematic review and Meta-analysis[J]. J Endourol, 2014, 28(9): 1107-1114. DOI: 10.1089/end.2014.0188.

23. Cornu JN, Ahyai S, Bachmann A, et al. A Systematic review and Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: an update[J]. Eur Urol, 2015, 67(6): 1066-1096. DOI: 10.1016/j.eururo.2014.06.017.

24. Al-Rawashdah SF, Pastore AL, Salhi YA, et al. Prospective randomized study comparing monopolar with bipolar transurethral resection of prostate in benign prostatic obstruction: 36-month outcomes[J]. World J Urol, 2017, 35(10): 1595-1601. DOI: 10.1007/s00345-017-2023-7.

25. Mamoulakis C, Skolarikos A, Schulze M, et al. Results from an international multicentre double‐blind randomized controlled trial on the perioperative efficacy and safety of bipolar vs monopolar transurethral resection of the prostate[J]. BJU Int, 2012, 109(2): 240-248. DOI: 10.1111/j.1464-410X.2011.10222.x.

26. 施斌, 陈柯宇. 等离子与汽化电切术治疗前列腺增生的效果及术后膀胱颈挛缩的影响因素[J]. 中华腔镜泌尿外科杂志(电子版), 2022, 16(2): 116-119. [Shi B, Chen KY. Effect of transurethral plasma kinetic resection of prostate and transurethral vaporization of prostate on benign prostatic hyperplasia and influencing factors of bladder neck contracture after operation[J]. Chin J Endourol(Electronic Edition), 2022, 16(2): 116-119.] DOI: 10.3877/cma.j.issn.1674-3253.2022.02.005.

27. Bouhadana D, Nguyen DD, Zhang X, et al. Safety and efficacy of TURP vs. laser prostatectomy for the treatment of benign prostatic hyperplasia in multi-morbid and elderly individuals aged≥75[J]. World J Urol, 2021, 39(12): 4405-4412. DOI: 10.1007/s00345-021-03779-2.

28. 王光宇, 周婷, 王自建. 前列腺增生并高血压患者采用经尿道等离子电切术治疗的临床观察[J]. 心血管病防治知识, 2022, 12(13): 19-21. [Wang GY, Zhou T, Wang ZJ. Clinical observation of transurethral plasma electrocautery treatment in patients with benign prostatic hyperplasia and hypertension[J]. Prevention and Treatment of Cardiovascular Disease, 2022, 12(13): 19-21.] DOI: 10.3969/j.issn.1672-3015(x).2022.13.005.

29. 吴玉军. 经尿道等离子电切治疗前列腺增生合并高血压患者的安全性及效果探讨[J]. 中西医结合心血管病电子杂志, 2022, 10(7): 69-71. [Wu YJ. Safety and efficacy of transurethral plasma electrocautery in patients with benign prostatic hyperplasia and hypertension: a discussion[J]. Cardiovascular Disease Electronic Journal of Integrated Traditional Chinese and Western Medicine, 2022, 10(7): 69-71.] DOI: 10.16282/j.cnki.cn11-9336/r.2022.07.043.

30. Netsch C, Stoehrer M, Brüning M, et al. Safety and effectiveness of Thulium VapoEnucleation of the prostate (ThuVEP) in patients on anticoagulant therapy[J]. World J Urol, 2013, 32(1): 165-172. DOI: 10.1007/s00345-013-1093-4.

31. Yuan J, Wang H, Wu G, et al. High-power (80 W) potassium titanyl phosphate laser prostatectomy in 128 high-risk patients[J]. Postgrad Med J, 2008, 84(987): 46-49. DOI: 10.1136/pgmj.2007.062711.

32. Magno C, Mucciardi G, Galì A, et al. Transurethral ethanol ablation of the prostate (TEAP): an effective minimally invasive treatment alternative to traditional surgery for symptomatic benign prostatic hyperplasia (BPH) in high-risk comorbidity patients[J]. Int Urol Nephrol, 2008, 40(4): 941-946. DOI: 10.1007/s11255-008-9394-z.

33. Autorino R, Damiano R, Di Lorenzo G, et al. Four-year outcome of a prospective randomised trial comparing bipolar plasmakinetic and monopolar transurethral resection of the prostate[J]. Eur Urol, 2009, 55(4): 922-929. DOI: 10.1016/j.eururo.2009.01.028.

34. Madersbacher S, Alivizatos G, Nordling J, et al. EAU 2004 Guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH Guidelines)[J]. Eur Urol, 2004, 46(5): 547-554. DOI: 10.1016/j.eururo.2004.07.016.

35. Thomas AW, Cannon A, Bartlett E, et al. The natural history of lower urinary tract dysfunction in men: minimum 10-year urodynamic followup of transurethral resection of prostate for bladder outlet obstruction[J]. J Urol, 2005, 174(5): 1887-1891. DOI: 10.1097/01.ju.0000176740.76061.24.

36. Li S, Zeng XT, Ruan XL, et al. Holmium laser enucleation versus transurethral resection in patients with benign prostate hyperplasia: an updated systematic review with Meta-analysis and trial sequential analysis[J]. PLoS One, 2014, 9(7): e101615. DOI: 10.1371/journal.pone.0101615.

37. Rassweiler J, Teber D, Kuntz R, et al. Complications of transurethral resection of the prostate (TURP)—incidence, management, and prevention[J]. Eur Urol, 2006, 50(5): 969-980. DOI: 10.1016/j.eururo.2005.12.042.

38. Ho HSS, Yip SKH, Lim KB, et al. A Prospective randomized study comparing monopolar and bipolar transurethral resection of prostate using transurethral resection in saline (TURIS) system[J]. Eur Urol, 2007, 52(2): 517-522. DOI: 10.1016/j.eururo.2007.03.038.

39. Singh H, Desai MR, Shrivastav P, et al. Bipolar versus monopolar transurethral resection of prostate: randomized controlled study[J]. J Endourol, 2005, 19(3): 333-338. DOI: 10.1089/end.2005.19.333.

40. Iori F, Franco G, Leonardo C, et al. Bipolar transurethral resection of prostate: clinical and urodynamic evaluation[J]. Urology, 2008, 71(2): 252-255. DOI: 10.1016/j.urology.2007.09.064.

41. 赖建生, 夏强, 郑东升, 等. 经尿道等离子双极电切及经尿道电汽化治疗前列腺增生症效果比较[J]. 中国医师进修杂志, 2003, (22): 19-21. [Lai JS, Xia Q, Zheng DS, et al. Comparative evaluation of transurethral bipolar plasmakinetic prostatectomy and transurethral electrovaporization for the treatment of benign prostatic hyperplasia.[J]. Chinese Journal of Postgraduates of Medicine, 2003, (22): 19-21.] https://www.cnki.com.cn/Article/CJFDTOTAL-YSJX200322007.htm.

42. Botto H, Lebret T, Barré P, et al. Electrovaporization of the prostate with the Gyrus device[J]. J Endourol, 2001, 15(3): 313-316. DOI: 10.1089/089277901750161917.

43. De Sio M, Autorino R, Quarto G, et al. Gyrus bipolar versus standard monopolar transurethral resection of the prostate: a randomized prospective trial[J]. Urology, 2006, 67(1): 69-72. DOI: 10.1016/j.urology.2005.07.033.

Popular Papers
© 2022 - 2024 Zhongnan Medical Journal Press of Zhongnan Hospital of Wuhan University|Support: Yufu Technology
About NM | Contact us